Pharmacosmos assumes global rights to lerociclib outside Asia-Pacific

Denmark, oncology-based Pharmacosmos today announced that it has assumed the worldwide rights, excluding select Asia-Pacific territories, to the investigational oncology asset lerociclib.

The company explained that these rights were previously out-licensed by G1 Therapeutics, the original developer of lerociclib, to Pepper Bio and Deimos Biosciences. Following Pharmacosmos’ acquisition of G1 Therapeuticsin September 2024, both license agreements have been concluded and the rights have transitioned back to Pharmacosmos.

Lerociclib is an investigational oral, selective CDK4/6 inhibitor that is designed to disrupt cancer cell proliferation by blocking cell cycle progression from the G1 to S phase. The compound holds the potential to be developed as a treatment for a number of solid tumors including hormone receptor-positive/HER2- negative (HR+/HER2−) advanced or metastatic breast cancer and hepatocellular carcinoma (HCC), the most common form of liver cancer. Lerociclib is currently under regulatory review in China for the treatment of HR+/HER2− advanced breast cancer, based on positive Phase III clinical data.